Keyphrases
Metformin
100%
Retrospective Cohort Study
100%
COVID-19
100%
Diabetes Medications
100%
COVID-19 Outcomes
100%
Dipeptidyl peptidase-4 (DPP-4)
75%
Ventilation
75%
Sulfonylurea
75%
Metformin Use
75%
Type 2 Diabetes Mellitus (T2DM)
50%
Severe COVID-19
50%
Early Outpatient Treatment
50%
Clinically Significant
25%
Mechanical Ventilation
25%
Diabetes
25%
Monotherapy
25%
Vaccination
25%
Randomized Trial
25%
Single Center
25%
Pre-exposure Prophylaxis (PrEP)
25%
Low Risk
25%
Hospitalization
25%
In Silico
25%
Observational Data
25%
Latinx
25%
Negative Control
25%
Viral Life Cycle
25%
New User
25%
Adult children
25%
User Study
25%
Observational Analysis
25%
SARS-CoV-2 Pandemic
25%
Negative Control Outcome
25%
Retrospective Cohort Analysis
25%
Back Pain
25%
Active Comparator
25%
Coronavirus Disease (COVID)
25%
Life Cycle Data
25%
Medicine and Dentistry
Diabetes
100%
Retrospective Cohort Study
100%
Glycon
100%
COVID-19
71%
Dipeptidyl Peptidase-4 Inhibitor
42%
Severe Acute Respiratory Syndrome Coronavirus 2
42%
Sulfonylurea
42%
Outpatient
28%
Type 2 Diabetes
28%
Infection
14%
In Vitro
14%
Maturity Onset Diabetes of the Young
14%
Cohort Analysis
14%
Monotherapy
14%
In Silico
14%
Body Mass Index
14%
Artificial Respiration
14%
Post-Exposure Prophylaxis
14%
Viral Life Cycle
14%
Severe Acute Respiratory Syndrome
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Metformin
100%
Sulfonylurea
42%
SARS Coronavirus
42%
Dipeptidyl Peptidase IV Inhibitor
42%
Infection
14%
Severe Acute Respiratory Syndrome
14%
Monotherapy
14%
Non Insulin Dependent Diabetes Mellitus
14%